Clobetasol propionate is a corticosteroid used to treat skin conditions such as eczema, contact dermatitis, seborrheic dermatitis and psoriasis. It is applied to the skin in the form of a cream, ointment or shampoo. It should only be used for short periods of time and only when other weaker corticosteroids are not effective. Its use is not recommended for rosacea or perioral dermatitis.
Pharmacodynamics
Clobetasol acts because of its structural similarity to endogenous glucocorticoids. Unbound, it can penetrate the membrane of the cell and then bind with high affinity to intracellular glucocorticoid receptors.
The anti-inflammatory (anti-inflammatory) effect is achieved by interfering with the so-called arachidonic acid metabolism. Clobetasol causes fewer prostaglandins and leukotrienes to be produced at the end of this metabolism. These are significantly involved in the inflammatory process of the human body.
Clobetasol has an anti-allergic effect by preventing the release of histamine and simultaneously reducing the number and activity of certain B and T lymphocytes.
Common side effects include skin irritation, dry skin, redness, pimples, and telangiectasia. Serious side effects may include adrenal suppression, allergic reactions, cellulitis, and Cushing's syndrome. Use in pregnancy and lactation is of uncertain safety.
LD50 (rat, oral): > 3000 mg-kg-1
| ATC Code | D07AD01 |
| Formula | C25H32ClFO5 |
| Molar Mass (g·mol−1) | 466,97 |
| Physical State | solid |
| Melting Point (°C) | 196.25 |
| CAS Number | 25122-46-7 |
| PUB Number | 5311051 |
| Drugbank ID | DB11750 |
Ad
